Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

Dr. Reddy's Laboratories Ltd. closed 16.92% below its 52-week high of 1,420.20 rupees, which the company reached on August ...

CEO of Dr Reddy's Laboratories, Erez Israeli believes his company's affordable medicines benefit the U.S. market and will be ...

Dr. Reddy's Laboratories Ltd. 500124 shares slipped 2.23% to 1,197.40 Indian rupees Monday, on what proved to be an ...

Welcome to the Dr Reddys Stock Liveblog, your ultimate source for real-time updates and analysis of one of the most prominent ...

Dr Reddy's Laboratories Ltd (RDY) reports a robust 16% YoY revenue growth, driven by strategic product launches and market ...

Stay up-to-date with the Dr Reddys Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on a prominent stock. Explore the latest information on Dr Reddys, including: ...

up 15.81% Y-o-Y Jan 28 2025 01:32 PM Hold Dr Reddys Laboratories; target of Rs 1245: KR Choksey Jan 27 2025 12:36 PM Neutral Dr Reddys Labs; target of Rs 1330: Motilal Oswal Jan 24 2025 01:19 PM ...

Dr Reddy's Laboratories (DRL) share price plunged 6.66 per cent to Rs 1,203.50 per share on the NSE during Friday after ...

Barclays analyst Balaji Prasad maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report) today and set a price target of ...

Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...

Stock Market today: Dr Reddy's Laboratories share price declined more than 6% in the morning trades on Friday post Q3 results that were announced after the market hours of Thursday ...